Viking Therapeutics, Inc. (VKTX)

NCM – Real Time Price. Currency in USD

33.98

+0.18 (0.53%)

Market open: Aug 12, 2026, 2:29 PM EDT

33.86

+0.06 (0.18%)

Previous after-hours: Aug 11, 2026, 7:59 PM EDT

08.08.2026

Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?

Eli Lilly leads the GLP-1 market and could remain on top thanks to a deep pipeline. Viking Therapeutics' leading GLP-1 candidate looks very promising.

07.08.2026

Viking Therapeutics: Mysterious GLP-1 Player With A Key Catalyst Due Q3 (Q2 Earnings Overview)

Viking Therapeutics (VKTX) maintains a Hold rating as competitive pressures intensify in the GLP-1 obesity drug space and key data catalysts approach. VKTX's lead asset VK2735 is in large Phase 3 VANQUISH trials, but efficacy expectations are high, and prior data is limited to a small, short Phase 2 study. A pivotal Q3 catalyst is the maintenance dosing study for VK2735; results could drive price volatility and influence funding needs amid high cash burn.

06.08.2026

Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished

Cash burn and potential dilution are key investor concerns. The company's phase 3 trials remain on track, and investors are awaiting results from a maintenance trial this quarter.

Videos

No Data

There is no data to display

Viking Therapeutics, Inc. (VKTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Viking Therapeutics, Inc. (VKTX)

Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?

Viking Therapeutics: Mysterious GLP-1 Player With A Key Catalyst Due Q3 (Q2 Earnings Overview)

Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished

Videos

No Data

Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?

Viking Therapeutics: Mysterious GLP-1 Player With A Key Catalyst Due Q3 (Q2 Earnings Overview)

Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished

Videos

No Data

Search stocks

Viking Therapeutics, Inc. (VKTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Viking Therapeutics, Inc. (VKTX)

Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?

Viking Therapeutics: Mysterious GLP-1 Player With A Key Catalyst Due Q3 (Q2 Earnings Overview)

Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished

Videos

No Data

Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?

Viking Therapeutics: Mysterious GLP-1 Player With A Key Catalyst Due Q3 (Q2 Earnings Overview)

Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished

Videos

No Data